** Arcus Biosciences shares RCUS.N drop 4% to $12.57 premarket
** Arcus's 13.6 mln stock offering priced at $11 each, a 16% discount to last close
** Co plans to use gross proceeds of ~$150 mln to develop its experimental kidney cancer drug and for other purposes
** Goldman Sachs, Leerink Partners and Evercore ISI were joint book-runners
** Prior to offering, RCUS had 91.5 mln outstanding shares for $1.20 bln market cap, per LSEG data
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。